Recent 8-K filings for CYCN

• April 1, 2026, 7:59 PM ET M&A materiality 0.90 neutral item 1.01item 5.01item 5.02item 7.01item 9.01 ◈ Material Agreements

  Cyclerion to merge with Korsana in reverse merger; $380M PIPE; CVRs for legacy assets

  Merger: pre-Merger Korsana stockholders own ~1.5% of combined co (pre-PIPE); Cyclerion shareholders ~98.5%.

• February 17, 2026, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Cyclerion receives positive FDA feedback for CYC-126 Phase 2 POC study in TRD; remains on track for 2H 2026 initiation

  Received positive pre-IND written feedback from FDA supporting CYC-126 Phase 2 POC study design in treatment-resistant depression (TRD).

• January 6, 2026, 6:59 PM ET other material materiality 0.80 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  Cyclerion Therapeutics enters collaboration with Medsteer for CYC-126 anesthetic delivery system

  Cyclerion entered a Collaboration and Option Agreement with Medsteer for an anesthetic delivery system for treatment-resistant depression.

• September 23, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01

  Cyclerion licenses MIT tech for treatment-resistant depression; relaunches as neuropsychiatry company

  Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.

• December 17, 2024, 6:59 PM ET other material materiality 0.60 positive item 1.01item 7.01item 9.01

  Cyclerion secures $1.75M from praliciguat license amendment, signs olinciguat option deal

  Akebia to pay Cyclerion $1.25M by Dec 31, 2024, and $500k by Sep 30, 2025; assumes IP costs after Q1 2025.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.53 · Most common event other_material

4 positive 0 negative 8 neutral

source · CYCN on sec.gov